Compare Quest Diagnostics Inc (DGX) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Huntington Bancshares Incorporated — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Huntington Bancshares Incorporated trades at $18.08 (market cap $36.18B). The key difference: Huntington Bancshares Incorporated is the larger of the two by market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| DGX | HBAN | |
|---|---|---|
Market Cap | $22.80B | $36.18B |
Sector | Health | Financials |
52-Week High | $216.02 | $19.27 |
52-Week Low | $166.42 | $15.02 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Huntington Bancshares (HBAN) trades at $17.93, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, and maintains a net income margin of 25.13%. Recent news highlights expansion in Texas and a fintech partnership award. Analyst consensus is a Buy with a $20.25 price target, suggesting potential upside.
HBAN presents a favorable outlook with earnings growth potential, supported by strategic acquisitions and solid fundamentals. Risks include integration challenges from recent M&A and competitive pressures in regional banking. The stock's current valuation below consensus target indicates room for appreciation, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
